Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03194685 · ClinicalTrials.gov registry record · Phase 1
Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Fujifilm Pharmaceuticals U.S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
NCT03194685 is a Phase 1 study that has completed, run by Fujifilm Pharmaceuticals U.S.A.. The registered enrollment target is 97 participants.
The verdict
NCT03194685, a Phase 1 study, has completed, sponsored by Fujifilm Pharmaceuticals U.S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
A Phase 1 dose escalation and dose ranging study of FF-10101-01 in subjects with relapsed or refractory acute myeloid leukemia to determine the safety, tolerability, PK and preliminary efficacy. A total of 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD).
Interventions
- DRUG FF-10101-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2017-05-05 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03194685
The ClinicalTrials.gov registry entry for NCT03194685 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fujifilm Pharmaceuticals U.S.A., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FF-10101-01 is the first listed.
NCT03194685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03194685 about?
NCT03194685 is a clinical study titled "Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia". A Phase 1 dose escalation and dose ranging study of FF-10101-01 in subjects with relapsed or refractory acute myeloid leukemia to determine the safety, tolerability, PK and preliminary efficacy. A total of 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD).
What is the current status of trial NCT03194685?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2017-05-05. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT03194685?
The interventions under investigation include: FF-10101-01 (DRUG).
Who is sponsoring clinical trial NCT03194685?
This trial is sponsored by Fujifilm Pharmaceuticals U.S.A., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.